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ABSTRACT
Introduction A Low Glycaemic Index (LGI) diet is a 
proposed lifestyle intervention in non- alcoholic fatty 
liver diseases (NAFLD) which is designed to reduce 
circulating blood glucose levels, hepatic glucose influx, 
insulin resistance and de novo lipogenesis. A significant 
reduction in liver fat content through following a 1- 
week LGI diet has been reported in healthy volunteers. 
Changes in dietary fat and carbohydrates have also 
been shown to alter gut microbiota composition and 
lead to hepatic steatosis through the gut- liver axis. 
There are no available trials examining the effects of 
an LGI diet on liver fat accumulation in patients with 
NAFLD; nor has the impact of consuming an LGI diet 
on gut microbiota composition been studied in this 
population. The aim of this trial is to investigate the 
effects of LGI diet consumption on liver fat content and 
its effects on gut microbiota composition in participants 
with NAFLD compared with a High Glycaemic Index 
(HGI) control diet.
Methods and analysis A 2×2 cross- over randomised 
mechanistic dietary trial will allocate 16 participants 
with NAFLD to a 2- week either HGI or LGI diet 
followed by a 4- week wash- out period and then the 
LGI or HGI diet, alternative to that followed in the first 
2 weeks. Baseline and postintervention (four visits) 
outcome measures will be collected to assess liver 
fat content (using MRI/S and controlled attenuation 
parameter- FibroScan), gut microbiota composition 
(using 16S RNA analysis) and blood biomarkers 
including glycaemic, insulinaemic, liver, lipid and 
haematological profiles, gut hormones levels and 
short- chain fatty acids.
Ethics and dissemination Study protocol has been 
approved by the ethics committees of The University of 
Nottingham and East Midlands Nottingham- 2 Research 
Ethics Committee (REC reference 19/EM/0291). Data 
from this trial will be used as part of a Philosophy 
Doctorate thesis. Publications will be in peer- reviewed 
journals.
Trial registration number NCT04415632.
INTRODUCTION
Non- alcoholic fatty liver disease (NAFLD) is 
a growing global health concern increasing 
in parallel with the worsening epidemics 
of obesity and diabetes.1 2 Recent reviews 
indicated that one billion people world-
wide have NAFLD (estimated prevalence 
25.4%).3 NAFLD is characterised by the fat 
accumulation in hepatocytes exceeding 5% 
of liver weight and encompasses a spectrum 
of disease severities. Common clinical risk 
factors that are highly associated with NAFLD 
include obesity, insulin resistance, type 2 
diabetes and metabolic syndrome.3 4 NAFLD 
is recognised as the hepatic manifestation of 
metabolic syndrome.5–7
Western dietary habits occurring concurrently 
with a sedentary lifestyle and genetic factors are 
associated with insulin resistance, adipocyte 
Strengths and limitations of this study
 ► A carefully controlled human Low Glycaemic Index 
diet intervention to reduce liver fat in non- alcoholic 
fatty liver diseases (NAFLD) using cross- over study 
deign.
 ► The first NAFLD patient study that explores the 
mechanistic effects of dietary glycaemic index on 
liver fat accumulation using advanced MR protocols.
 ► Uses the controlled attenuation parameter as a bio-
marker to evaluate efficacy of diet intervention.
 ► Findings from small sample size may not be gen-
eralisable to all patients with NAFLD so will require 
replication in larger long- term randomised con-
trolled trial.
 ► The 2- week time frame of the intervention, especial-
ly in light of isoenergetic diet, may not be sufficient 
to observe significant changes in liver fat.
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proliferation and gut microbiota alteration which may be 
implicated in NAFLD.8 Dietary habits, hormones secreted 
from the adipose tissue, gut microbiota composition and 
genetic factors are all implicated in the pathogenesis.
To date, there are no drugs with regulatory approval for 
treating NAFLD, and lifestyle changes including modification 
of dietary patterns together with increased physical activity is 
the initial step to treat this disease.9 Dietary approaches bene-
ficial in NAFLD management include reductions in saturated 
and trans fatty acids, total carbohydrates and animal- based 
protein intake and increases in the intake of polyunsaturated 
fatty acids, monounsaturated fatty acids, plant- based proteins 
and antioxidants.4 Furthermore, evidence from a systematic 
review and meta- analysis of randomised controlled trials 
(RCTs) on patients with NAFLD has shown that lifestyle- 
induced weight loss of ≥7% improved histological disease 
activity, as well as cardiometabolic risk profile, in less than 
50% of the study population (n=373 patients).10 A recent 
systematic review has concluded that despite the abundance 
of interventional studies on dietary management in NAFLD, 
there is still a lack of evidence- based specific recommenda-
tions, other than that weight loss may benefit some; and few 
studies have measured liver- related outcomes.11 Moreover, 
the dietary effects on liver- related outcomes that are medi-
ated by gut microbiome have not been studied in these 
patients.12
More recently, the Glycaemic Index (GI) and glycaemic 
load (GL), of diet; has been proposed as an important 
predictor of NAFLD progression.4 13 The GI of a food 
ranks the glycaemic response under conditions in which 
the quantity of carbohydrate is controlled,14 15 whereas 
the GL additionally considers portion size.16
NAFLD patients have been found to consume a diet 
high in High GI (HGI) foods4 which are correlated with 
insulin resistance, metabolic dysfunction,4 and liver 
dysfunction.17 In addition, HGI dietary habits have been 
significantly associated with high- grade liver steatosis 
in patients with insulin resistance18 while limiting HGI 
foods is beneficial in NAFLD.19 20 Further, previous pilot 
study showed that only 1 week of consuming HGI diet 
caused significant increase in hepatic stores of fat when 
compared with isocaloric Low GI (LGI) diet consump-
tion.21 A recent review concluded that both low GI and 
GL diets resulted in significant reductions in hepatic fat 
mass in a cohort of 269 participants.16 However, these 
effects were not attributed to the LGI diet alone and were 
confounded with other lifestyle interventions.16
Evidence from animal and human studies also showed 
that diet is the most important modifying factor in the 
development of human gut microbiome.22–24 Dietary 
alterations can rapidly change the human gut microbiota 
composition in relatively short time periods25–27 and in as 
little as 24 hours.28–30 Certain dietary factors which modify 
gut microbiota have been associated with a number of 
diseases including obesity31 metabolic syndrome,22 32 33 type 
2 diabetes,34 immunological dysfunctions.35 Such dysbi-
osis in diet- induced NAFLD has been shown to stimulate 
hepatic fat disposition and promote NAFLD progression to 
non- alcoholic steatohepatitis (NASH).36 37 This is suggested 
to be mediated by modulation of gut permeability, dietary 
choline metabolism, bile acid metabolism, endogenous 
ethanol production and immune balance.36 37 Gut micro-
biota modulated by diet can increase the energy extraction 
from the breakdown of non- absorbable polysaccharides with 
the production of monosaccharides and short chain fatty 
acids (SCFAs) which are substrates for hepatic de novo lipo-
genesis and carbohydrate biosynthesis.38 Certain SCFAs have 
also been implicated in improving glucose and lipid metab-
olism beneficial to the host.39 Therefore, there is a potential 
to modulate gut microbiota through dietary changes as a 
means of NAFLD prevention or alleviation.11 40
We describe here our study protocol designed to assess 
the effects of a specific defined GI dietary manipula-
tion21 on liver fat content and its effects on gut micro-
biota composition in participants with NAFLD compared 
with a higher GI diet as a control diet. The diets will be 
adjusted to each participant to meet their energy require-
ments and the macronutrient composition of the diets 
will be carefully controlled ensuring that differences in 
GL are due to differences in GI.
OBJECTIVES
Primary objective
1. To investigate the effects of defined LGI versus HGI diet on 
liver fat accumulation in participants with NAFLD following 
a 2- week intervention period while controlling for the energy 
consumption and amount of carbohydrate intake.
Secondary objectives
1. To investigate the effects of LGI versus HGI diet on 
gut microbiota composition and its correlations with 
liver outcomes in participants with NAFLD following a 
2- week intervention period.
2. To investigate the changes in blood metabolic bio-
markers (glycaemic, insulinaemic, liver, lipid, haema-
tological profiles, gut hormones and plasma SCFAs) 
between LGI and HGI diet groups following a 2- week 
intervention in participants with NAFLD.
3. To evaluate controlled attenuation parameter (CAP) 
as a tool to test the efficacy of a dietary intervention by 
comparing its performance characteristics with that of 
MR Spectroscopy (MRS) as a gold standard.
4. To validate the European Prospective Investigation of 
Cancer Food Frequency Questionnaire (EPIC- FFQ) in 
Nottingham NAFLD patients against food diary.
METHODS AND ANALYSIS
Trial design
This is a randomised 2×2 cross- over mechanistic trial 
including two arms, each of 2 weeks duration comparing 
an LGI diet and a control HGI diet based on that defined 
by Bawden et al21 and Morgan et al.41 The study design is 
illustrated in figure 1.
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Public and patient involvement
We collaborated with the National Institute of Health 
Research (NIHR) Nottingham Biomedical Research 
Centre (BRC) patient advisory group, and we met seven 
patients who were interested in study participation. 
They expressed strong support for the research objec-
tives and the recent meeting the group considered the 
2- week cross- over intervention feasible and acceptable. 
Patient feedback informed the participant recruitment 
through information content and delivery methods. They 
also assisted in the study design to enhance participant 
compliance and commitment to the diet.
Participants and recruitment
We aim to recruit 16 participants with NAFLD to complete 
both phases of 2×2 cross- over trial. The initial screening 
criteria for inclusion is a CAP score of >288 dB/m; this 
value correlates with MRI- Proton Density Fat Fraction 
(PDFF) estimation of >5% fat of liver weight which indi-
cates that they have a fatty liver.42
NAFLD patients will be recruited either from the 
existing database of ‘The Scarred Liver Project’ in the 
UK who have given consent to be contacted to participate 
in future research (approved by East Midlands- Leicester 
Research ethics committee ref: B/EM/0123) or from 
liver clinics at the Nottingham University Hospitals NHS 
Trust who had a FibroScan with CAP or participants from 
public (advert in local and social media). The eligibility 
criteria are summarised in box 1. All participants will 
provide a written informed consent by trained research 
team before they enter the trial. Potential participants 
will be free to withdraw at any time. In the event of their 
withdrawal, it will be explained that their data collected 
so far cannot be erased and we will seek consent to use 
the data in the final analyses where appropriate. In the 
event of a participant withdrawing or being unable to 
continue the intervention periods after randomisation, 
a replacement will be recruited who will be assigned to 
the same diet group to ensure a 1:1 ratio for the two diet 
groups. We will continue recruiting until 16 participants 
have fully completed the study.
Screening process
Participants will be invited to attend an initial screening 
visit (figure 1). At this visit, participants will be consented 
and asked to complete a prescreening questionnaire 
(including taking height, weight and blood pressure 
measurements) to establish whether they meet the study 
criteria. Participants will be asked to fill out a 7- day food 
record and post it after 1 week of their initial screening 
visit. This is to avoid giving patients with NAFLD, who 
might be at risk of developing diabetes, a much higher 
Figure 1 Schematic diagram for cross- over trial of LGI diet 
versus HGI diet effects on liver fat content in participants 
with NAFLD. FFQ, Food Frequency Questionnaire; HGI, 
High Glycaemic Index; IPAQ, International Physical Activity 
Questionnaire; LGI, Low Glycaemic Index; NAFLD, non- 
alcoholic fatty liver diseases.
Box 1 Eligibility criteria
Inclusion criteria
 ► Adult males and females aged from 18 to 65 years (balanced 
number).
 ► Detected non- alcoholic fatty liver diseases (NAFLD) by controlled at-
tenuation parameter (CAP)- FibroScan >288 dB/m or by MRI- proton 
density fat fraction >5% fat of liver weight.
 ► Body mass index ≥25 kg/m2.
 ► Abdominal obesity (waist circumference >102 cm for males and 
>88 cm for females).
 ► Have current moderate to high Glycaemic Index diet intake of ≥60 
(Assessed from a completed 7- day day food diary).
 ► Available to give informed consent.
 ► Available to undergo MRI/spectroscopy and CAP- FibroScan.
Exclusion criteria
 ► Current smokers and excessive alcohol drinkers (>14 units/week).
 ► Perimenopausal (irregular periods) women.
 ► Participants with other liver abnormalities.
 ► Participants with history of gastrointestinal surgeries, depression, 
eating disorders or difficulties.
 ► Participants using pharmacological agents for obesity or NAFLD.
 ► Participants with type 1 diabetes.
 ► Participants with type 2 diabetes on second line medications (eg, 
glucagon- like peptide- 1 analogues).
 ► Participation in any other trial in the last 3 months.
 ► Participants on any special diets (eg, vegetarians).
 ► Intolerance to foods included in the diet plan.
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HGI diet than they habitually consume. Using 7- day 
food records, we will characterise the baseline habitual 
GI diet intake of all potential volunteers at screening 
period. Participants also will be required to complete 
a FFQ for validation against the 7- day food records. We 
will use EPIC- FFQ that was validated for use in Norfolk 
cohort.43 After completion, participant’s eligibility will 
be reassessed based on analysis of diet information using 
Nutritics software (Nutritics, Dublin, Ireland, 2018). 
Those with a habitual LGI diet intake (GI <60) will be 
excluded from the study. Only patients who have a 
moderate to HGI diet intake (GI ≥60) will be invited to 
attend the next screening preparation visit.
Then at next screening visit (visit 2), the participants will 
be asked to fill out International Physical Activity Question-
naire (IPAQ).44 A trained dietitian will instruct participants 
on how to measure study food provided using measuring jug 
and spoons and how to fill in study diet compliance sheets. 
They will be instructed on stool collection and preinterven-
tion visits requirements. Participants will be asked to avoid 
eating probiotics and/or prebiotics supplements or drinks 
for 1 week before the intervention period (standardisation 
week). All instructions will be provided to each participant 
in a form of Home Guide Booklet.
Each eligible participant will be assigned randomly to 
undergo either HGI diet (HGI group) or LGI group first 
and then crossover to either HGI or LGI diets.
Randomisation and blinding
Enrolled participants who meet the eligibility criteria will 
be randomised to one of two groups which will dictate the 
order in which they receive the LGI or HGI diet. They 
will then receive the second diet depending on which diet 
they have first received. The random allocation sequence 
(AB or BA) will be generated by one of the trial co- ordina-
tors; who will have no contact with the participants, using 
block randomisation by impartial biostatistics. The online 
randomisation package (http:// randomization. com) will 
be used to allocate the sequences of the diet groups to the 
participants in equal numbers. Once the random number 
is generated, both trial investigators and participants are 
aware of the diet sequence (ie, whether the participant is 
going to start with LGI diet; A or HGI diet; B). The diets 
then will be delivered to the participant according to the 
sequence. The trial outcome measures will be determined 
by blinded researcher using codes on samples that will be 
sent for 16S ribosomal RNA (rRNA), blood marker and 
MRI/CAP- FibroScan analyses. The blinded allocation will 
be provided to the study statistician at the end of the study 
and once the analysis has been completed, the study stat-
istician will be provided with the unblinded allocation.
Study protocol
Following the screening phase and standardisation week, 
each participant will experience two, 2- week intervention 
phases, with a 4- week washout period between interven-
tions. Before and after each intervention period they will 
attend the Imaging Centre (Sir Peter Mansfield Imaging 
Centre) for MRI scan measurements and then will attend 
the Biomedical Research Centre for FibroScan, and 
blood and stool samples collection. During each interven-
tion phase each participant will be required to consume 
all the food that has been provided, fill in dietary compli-
ance sheets and complete Visual Analogue Scales (VAS) 
relating to subjective appetite ratings.
Design of the dietary interventions
Energy expenditure will be estimated for each partici-
pant using the individual’s basal metabolic rate calcu-
lated from Henry- modified Schofield formula45 and 
multiplied by an activity factor based on the IPAQ 
score physical activity levels. A menu, consisting of 
meals for 3 days personalised for energy requirement, 
will be devised (these meals are repeated over 2 weeks) 
by adjusting a template according to their estimated 
energy requirement in order to minimise weight 
change during the intervention phase. The diet consists 
of normal food closely resembling that described by 
Bawden et al study.21 A diet template of 2000 kcal/
day with energy proportions distributed as 55% from 
carbohydrates, 15% from protein and 30% from fat46 
are designed and food quantities will be modified to 
supply the energy requirements for each participant. 
Three- day cycle menu plans are designed for each diet 
(LGI/ HGI). Table 1 shows example template menus 
for both HGI (a) and LGI (b) diets.
The GI values of commercial food items are generated 
from that reported by Henry et al,47 as well as Nutritics 
software databases (Nutritics). The dietary GI of the 
menu is calculated from GI proportional contribution 
to total carbohydrate using the equation: GI=∑(Cfood/
Ctotal) × GIfood; where Cfood is the amount of carbohydrate 
contained in each digested food (g), Ctotal is the total 
carbohydrate in the meal and is the reported GI of the 
food.21 The GL of the diet is calculated based on the 
dietary GI and the amount of carbohydrate provided (the 
same in both diets) using the following equation: GL=(-
GIfood × Cfood)/100; where GI is the GI of each digested 
food and food is the amount of carbohydrate in the 
food.21 Food composition analysis and evaluation were 
performed using Nutritics software (Nutritics, Dublin, 
Ireland, 2018).
Participants will be provided with the food at the start 
of each 2- week diet period and will be clearly instructed 
on safe food storage and reheating. They will be required 
to complete dietary compliance sheet on a daily basis. 
Instructions on dietary compliance will be given at each 
study period and the dietary compliance records will 
be reviewed regularly during the intervention to assess 
their compliance. For the first 1 week prior to the inter-
vention (1- week standardisation), and during the 4- week 
wash- out period, participants will be asked to avoid eating 
probiotics, yoghurt and cultured milk drink; if any, to 
standardise their gut microbiota and avoid any carry- 
over effects as shown in previous studies.48 49 Meal- timing 
will be standardised among all participants as much as 
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possible during the intervention as well as during the 
standardisation period.
Data collection and analyses of outcome measures
The timing and frequency of study measurements are 
depicted in figure 1. Participants will be asked to come 
fasted (a minimum of 8 hours) for each laboratory visit 
(pre and post each intervention period) and the following 
measurements will be made:
1. Anthropometric measurements: Participant height 
(cm), weight (kg), waist circumference (cm), body 
mass index (BMI) (kg/m2) and body composition 
with bladder voided using bioelectrical impedance 
analysis Analisi Composizione Corporea (BIA- ACC) 
Table 1 Illustration of HGI (A) and LGI (B) diet templates for use in the study
Weight (g) Energy (kcal) Carbohydrates (g) Protein (g) Fat (g) Fibre (g) GI GL
HGI diet sample (A)
  Breakfast
   Sultana Bran Cereal 90 268 58 6.6 1.3 10.1 90 52.2
   Skimmed milk 180 63 8.3 6.3 0.54 0 48 4
   Roasted peanuts 15 90 2.3 3.7 7.4 1.3 14 0.32
   Glucose 10 40 10 0 0 0 100 10
   Water 170 0 0 0 0 0 0 0
   Meal total 461 78 16.6 9.2 11.4 85.3 66.5
  Lunch
   Margarine 25 102 0.13 0.05 11.3 0 0 0
   Fruit loaf 144 395 76 11.4 5.2 4.6 90 68.4
   Roasted turkey slice 42 47 0.67 10 0.5 0.12 0 0
   Cheddar cheese slice 25 104 0.03 6.4 8.7 0 0 0
   Strawberry yoghurt 125 88 16.3 5.6 0 0.38 85 13.855
   Meal total 735 93 33.4 25.7 5.1 88.44 82.255
  Dinner
   Cottage pie (ready meal) 400 441 44 18 21.6 4.8 66 29.04
   Low fat strawberry yoghurt 125 88 16.3 5.6 0 0.38 85 13.855
   Water 170 0 0 0 0 0 0 0
   Glucose 10 40 10 0 0 0 100 10
   Mars bar 58 237 37 2.4 8.9 0.87 65 24.05
   Meal total 806 107 26 30.5 6 72.69 76.954
  Menu total 2002 Kcal 278 g (55.5%) 76 g (15.2%) 65 g (29.3%) 22 g 82.1 225.706
LGI diet sample (B)
  Breakfast
   All Bran cereal 90 239 42 11.2 3.1 22.1 43 18.06
   Semi- skimmed milk 160 76 7.2 5.6 2.7 0 25 1.8
   Orange juice 250 96 22 1.5 0.25 0 53 11.66
   Meal total 410 71 18.2 6 22.1 44.39 31.52
  Lunch
   Pumpernickel bread 180 408 74 15.7 5.6 11.7 41 30.34
   Black cherry yoghurt 150 209 24.2 4.8 10.4 0.75 17 4.114
   Soft cheese 51 129 1.5 2.7 12.4 0 34 0.51
   Meal total 745 99 23.2 28.4 12.5 35.32 34.96
  Dinner
   Lasagne (ready meal) 290 413 42 21.5 17.7 4.9 36 15.12
   Apple 174 92 20 1 0.87 2.1 38 7.6
   Semi- skimmed milk 150 71 6.8 5.3 2.6 0 25 1.7
   Fruit and nuts mix 60 267 24.6 8.4 15 3.9 15 3.69
   Meal total 843 93 36.2 36.1 10.9 30.22 28.11
  Menu total 1999 kcal 264 g (52.7%) 78 g (15.5%) 71 g (31.8%) 46 g 36.64 94.594
GI, Glycaemic Index; GL, glycaemic load; HGI, High Glycaemic Index; LGI, Low Glycaemic Index.
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appliance model BIA00A; (BioTekna, Marcon VE, 
Italy).
2. Liver fat assessment: Hepatic fat fraction and com-
parison lipid composition will be measured using a 
Philips 3T Acheiva MRI scanner with 32 channel re-
ceive XL torso coil and advanced lipid composition 
analysis on a Philips 7T Acheiva scanner with eight 
channel multitransmit body coil. MRS will be acquired 
from a 20×20×20 mm voxel within the lower right lobe 
of the liver using Stimulated Echo Acquisition Mode 
localisation to assess hepatic fat fraction and compo-
sition. Spectra will be acquired over four echo times 
(20, 30, 40, 80) to correct for T2 relaxation over five 
breath- holds. Water will be used as a reference peak, 
and water suppression used to analyse signal from 
lipids. Spectra will be post processed (phase correct-
ed, line- broadened, frequency aligned and averaged) 
as described previously,50 and then fitted according 
to known lipid signal positions.51 T2 corrected PDFF 
will be calculated as PDFF=FAT/(FAT +WATER) and 
converted to true mass fat fraction using known tissue 
values.52 Lipid composition will be estimated using in-
dividual peak amplitudes.53 Subcutaneous and visceral 
fat volumes will be determined using gradient echo 
MRI.54
Liver fat levels will also be assessed with the CAP scored 
using FibroScan, which has previously been evaluated 
against MRS55 as well as liver biopsy56 in cross- sectional 
cohorts. Although MRI- PDFF more accurately classi-
fies steatosis,57 portability, accessibility and costs favour 
CAP associated with transient elastography. However, 
CAP has not been evaluated as a marker of efficacy of 
intervention. For the purpose of validation, partici-
pants will undergo a CAP- FibroScan at each interven-
tion visit to quantify their liver fat levels.
3. Hepatic ATP flux: Rate of mitochondrial ATP turn-
over in the liver will be assessed using a Philips 3T MRI 
scanner with a Philips Phosphorous (31P) single loop 
surface coil. 31P MRS will be acquired from the liver 
using a 60 mm thick slice to avoid contamination from 
abdominal muscle. A progressive saturation scan pro-
tocol (five spectra acquired with varying length pre-
saturation pulses) will be used to determine apparent 
T1.58 Two 31P MR spectra will then be acquired with 
full saturation of gamma ATP (−2.5ppm) and mirrored 
downfield of the inorganic phosphate peak (~14 ppm) 
respectively. An in- house fitting programme will be 
used for postprocessing spectra and measuring the sat-
uration transfer to the inorganic phosphate peak and 
used to determine hepatic ATP flux rate constant. ATP 
concentration will also be determined from spectra 
and used to calculate final ATP flux rate values.59
4. Metabolic Biomarkers: Blood samples (not more 
than 80 mL at each visit) will be taken from fasted 
participants (12- hours fast) for analyses of metabolic 
analytes such as: glycaemic, insulinaemic, liver, lip-
id, haematological profiles, gut hormones (ghrelin, 
leptin, glucagon- like peptide- 1 (GLP- 1), glucagon) 
and plasma SCFAs. Although GLP- 1 levels increase in 
response to meal ingestion, levels can be directly af-
fected by presence of SCFAs, produced from fermen-
tation of certain carbohydrates which may have been 
recently consumed, confounding the results. Instead, 
only fasting levels will be measured as short- term diets 
containing different carbohydrates types and different 
GI content have been found to affect fasting GLP- 1 
levels.60 In addition, circulating plasma SCFAs levels 
will be measured as it has been shown to be strongly 
related to metabolic health.61 Measurement of plasma 
SCFAs levels also overcomes the challenges associated 
with accurate quantification of volatile SCFAs mole-
cules in faecal samples.62
All biochemical parameters concentrations will be as-
sessed by a central laboratory that uses standard meth-
ods. Standard operating procedures will be followed 
for all laboratory assays to ensure the high quality and 
reliability of our generated data. Routine blood tests 
will be analysed by the accredited laboratories. Samples 
will be stored in −80 °C freezers until the study ends, 
under yearly service contract and monitoring systems. 
Analyses will be done according to assay manufacturer 
advice and completed by technicians and research staff 
who are formally trained or outsourced to collabora-
tors or external suppliers where necessary. The insulin 
resistance will be estimated using homeostatic model 
assessment of insulin resistance (HOMA- IR). HOMA- 
IR is calculated according to the equation (HOMA- IR 
= (FPI×FPG)/22.5); where FPI is fasting plasma insu-
lin, and FPG is fasting plasma glucose.4
5. Gut Microbiota Composition: Each participant will be 
asked to collect fresh stool sample in a standard lab-
oratory container and bring it to the research centre 
with an ice pack for storage at −80°C. Stool samples 
will be processed using a standard commercial kit for 
(DNA)extraction.63 Then, the gut microbiota compo-
sition will be assessed using 16S sequencing of rRNA. 
DNA will be diluted to 20 ng/µL for 16S rRNA am-
plification and sequencing. Water negative controls 
will be included from extraction, through PCR to se-
quencing and select samples were sequenced in du-
plicate for quality control. The V4 region of the 16S 
rRNA gene will be amplified using universal primers 
355F ( CCAG ACTC CTAC GGGA GGCAGC) and 806R ( 
GGACTACHVGGGTWTCTAAT). Amplified DNA will 
be sequenced on the MiSeq platform (Illumina). Read 
filtering and clustering will carried out using the MY-
crobiota pipeline. Briefly, chimeric sequences will be 
filtered using the VSEARCH algorithm within Mothur, 
and reads will be clustered into operational taxonomic 
units (OTUs) using closed- reference clustering against 
the SILVA database v132 based on a 97% similarity. Di-
versity metrics (Shannon index, observed OTUs and 
Unweighted UniFrac) will be calculated by rarefying 
the OTU table down to 7000 sequences per sample 50 
times and taking the average. These analyses will be 
carried out in QIIME V.2 (V.2018.11).64 65
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6. Subjective Sensation Assessments: VAS scores will 
be used to assess the participant’s subjective appe-
tite (hunger and fullness) during the intervention. 
Participants will be provided with a booklet to record 
their subjective appetite before and after each meal 
during the intervention at selected days.
Sample size calculation and justification
The sample size is calculated using nQuery based on 
previous completed study by Bawden et al.21 Based on 
their pilot data, baseline liver fat fractions of both diet 
groups were 2.4±1%–1.2%, and after 1 week were HGI 
(High GI)=4.7% ± 2% and LGI=1.6 ± 0.7%. Using a two- 
group t- test (cross- over analysis of variance (ANOVA)) 
between the post- diet values with a 0.05 two- sided signif-
icance level, this produces a sample size of n=8 in each 
diet sequence (a total sample size of 16). This sample 
size has an 80% power to detect a difference in means of 
3.1 (the difference between a Treatment 1, µ1, of 4.7 and 
a Treatment 2, µ2, of 1.6) with the assumption that the 
crossover ANOVA sqrt (MSE) is 2.828 (the SD of differ-
ences, σ, is 4). Assuming that 40% of people would drop 
out from cross- over study design, it is expected that at 
least 24 participants would need to be recruited.
The effect from the pilot study by Bawden et al pilot 
study (n=7) was an average 1.6%±0.7% decrease in liver 
fat fraction after following a 1- week LGI diet (p<0.05). 
Given that baseline liver fat fraction was 2.4%, in order 
to see such change with 80% power (p<0.05) we have 
doubled the participant numbers to n=16 using nQuery 
software to detect statistically significant differences.21 
Our group has recently completed a study ( ClinicalTrials. 
gov Identifier: NCT03844165) in which 84 participants 
with NAFLD followed either an LGI food enriched diet 
or their normal diet. Patients who changed their diet 
were found to have a significant decrease in liver fat after 
16 weeks (from 20.4% to 18.8%) and had a statistically 
significant decrease in fasting glucose levels after the diet 
compared with the control group patients following their 
normal diet. This provides strong support to our hypoth-
esis and demonstrates that a simple dietary change can 
have measurable impact on NAFLD symptoms in a short 
period. In another previous randomised crossover trial, 
metabolic changes were seen within 2 weeks in a dietary 
intervention with 10 participants.66 Based on these 
different approaches, we conclude that a sample size of 
16 at the end of the study is sufficient. Assuming a 33% 
drop- out rate we estimate that it will be necessary to enrol 
n=24 NAFLD participants to achieve n=16 completing 
the two diet- interventions. This dropout rate has been 
reported in other dietary interventional studies.67
Statistical analysis plan
Baseline characteristics of participants, outcome measures 
at baseline (liver fat content, blood biomarkers and gut 
microbial composition) at each period time point will be 
summarised by diet group using descriptive statistics. The 
differences between the two interventions (LGI and HGI 
diet) will be tested by matched- pair Student’s t- test. Two- 
way repeated measures ANOVA test will be used to eval-
uate the effects of diets and time sequences on liver fat 
content, as well as on gut microbial composition and blood 
biomarkers and/or interactions with liver fat content, gut 
microbial composition and blood biomarkers. Data will 
be presented as mean±SD and the significance of differ-
ence will be set at p<0.05. Any changes in the planned 
statistical methods will be documented in the trial report. 
Data input, cleaning and analysis will be conducted using 
Stata software package. All analyses will be conducted on 
University of Nottingham computers/laptops that are 
regularly backed up to University of Nottingham servers.
Microbiome analyses: OTUs with a relative abundance 
of <0.1% in every sample will be removed, and relative 
OTU abundances will be inverse normal transformed 
before further analysis. Associations between response 
to LGI diet and OTU abundance at genus level will be 
predicted using a general linear model adjusted for age, 
gender and BMI. OTUs will be assumed to be significantly 
associated with response to the dietary intervention with a 
value <0.05 after adjusting for false discovery rate.
Data management
Trial data will be managed by study coordinator (AA- A) 
under the supervision of chief investigator (GA) and 
study statistician. The study coordinator shall carry 
out monitoring of trial data as an ongoing activity and 
perform annual site system audit. Trial data and evidence 
of monitoring and systems audits will be made available 
for inspection by REC as required. The sponsor has the 
right to take advice from the Trial Steering Committee 
and Data Monitoring Committee as appropriate for 
study discontinuation. All trial staff and investigators 
will endeavour to protect the rights of the trial’s partic-
ipants to privacy and informed consent, and will adhere 
to the Data Protection Act, 2018. Access to the data will 
be limited to the trial staff and investigators and relevant 
regulatory authorities and will be restricted by user identi-
fiers and passwords (using a one- way encryption method). 
Computer held data including the trial database will be 
held securely and password protected. All data will be 
stored on a secure dedicated web server. Electronic data 
will be backed up every 24 hours to both local and remote 
media in encrypted format.
In compliance with the International Conference on 
Harmonisation Good Clinical Practice (Food and Drug 
Administration guideline) guidelines, regulations and in 
accordance with the University of Nottingham Research 
Code of Conduct and Research Ethics, the chief or local 
principal investigator will maintain all records and docu-
ments regarding the conduct of the study. These will be 
retained for at least 7 years or for longer if required. The 
Trial Master File and trial documents held by the Chief 
Investigator on behalf of the sponsor shall be finally 
archived at secure archive facilities at the University of 
Nottingham. This archive shall include all trial databases 
and associated meta- data encryption codes.
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Ethics and dissemination
Ethical approval was first obtained from the University of 
Nottingham, Medical School Research Ethics Committee. 
Then additional ethical approval was obtained from East 
Midlands Nottingham 2 Research Ethics Committee (The 
Old Chapel, Royal Standard Place, Nottingham). Within 
a 5- year time frame, the final anonymised trial data will be 
uploaded to the https:// rdmc. nottingham. ac. uk public 
repository after consistency and quality have been veri-
fied by the project team and publication of the results. 
Data from this trial are intended to be presented at local 
and international conferences including those attended 
by clinicians and dietitians and will also be used as part 
of a Philosophy Doctorate thesis. Publications will be in 
peer- reviewed journals. No participant will be identified 
in any of these publications.
DISCUSSION AND RESEARCH IMPLICATIONS
Building on previous findings from Morgan et al41 and 
Bawden et al,21 this study will investigate the effects of LGI 
versus HGI diets in participants diagnosed with NAFLD, 
over a 2- week period. While previous studies showed a 
significant impact of LGI on liver fat reduction and other 
metabolic biomarkers, questions remain on the effect in 
individuals with NAFLD and the longer- term impact. Due 
to the carefully controlled nature of the intervention, 
the sample size can be reduced, and the research used to 
probe more specifically into the direct effects of varying 
the type of carbohydrate intake. Many studies have shown 
that energy reduction has a profound effect on liver fat 
and metabolic health,68 but these diets have been found 
to be unsustainable in a community setting.10 Proof of 
the direct impact of varying a specific characteristic of 
one macronutrient without reducing the overall intake 
of the macronutrient consumed, or the overall energy 
consumed would provide a strong basis for further inves-
tigations on the sustainability of such diets.
This study takes advantage of advanced MR protocols 
which provide a powerful method for non- invasively 
assessing the effects of lifestyle interventions on metabolic 
health alongside other physiological measures. Biopsy 
measurements are uncomfortable for the patient carrying 
a number of significant risks and would be ethically inap-
propriate in otherwise healthy individuals. In addition, 
biopsy only provides a small sample from one region 
of the liver. MRI and MRS have been well validated52 69 
and allows for repeated tissue specific measurements of 
fat fraction with minimal risk to study volunteers, thus 
enabling robust longitudinal studies on the impact of 
nutrition on metabolic health and liver disease. Addi-
tionally, recent research has highlighted the potential 
significance of lipid composition in metabolic disorders 
and novel methodologies for measuring this using MRI 
and MRS have been developed.53 These advanced tech-
niques will be used to assess not only lipid accumulation 
but also the effect on saturated, unsaturated and polyun-
saturated fat stores in the liver. Subcutaneous and visceral 
fat volumes will also be obtained alongside hepatic fat 
fraction during the scan session giving a more complete 
picture of abdominal lipid deposition.
31P MRS measurements of hepatic ATP flux provides 
a novel and exploratory assessment of the impact of life-
style interventions on metabolism. Previous studies have 
shown the correlation of metabolic disorders such as 
NAFLD with impaired ATP turnover in the liver.70 Using 
advanced in vivo saturation transfer MR protocols, this 
study will monitor these effects during an intervention 
and provide the first in- human study to explore mecha-
nistic effects of diet on liver lipid accumulation. This will 
give a foundation for future research projects and help to 
advance the effort against the growing global pandemic 
of NAFLD and related disorders.
Outcomes from this study will provide evidence on 
the effects of an LGI diet consumption on measures 
of NAFLD and will serve as a complementary tool for 
reducing hepatic fat accumulation in NAFLD patients. It 
will also be the first to provide nutritional- related infor-
mation about the effects of LGI diet on gut microbiota 
composition in this medical condition. Accordingly, trial 
findings will open the way for academic beneficiaries 
(including dietitians, hepatologists, diabetologists) to 
develop a novel strategy for NAFLD monitoring through 
understanding the mechanism behind the LGI dietary- 
related effects of specific gut microbiota and hepatic fat 
accumulation.
In addition, the validation findings for the use of CAP- 
FibroScan as a new tool for assessing hepatic fat levels in 
dietary interventions has the potential to enhance diag-
nostic and research capacity. Furthermore, the valida-
tion of Norfolk EPIC- FFQ in Nottingham population will 
permit its use in larger population- based studies.
If this study successfully reproduces the reduction in 
hepatic fat levels through LGI diet reported in healthy 
volunteers21 in an NAFLD patient cohort, this will be 
a key step towards developing a new option for dietary 
intervention. The inclusion of LGI foods as a recommen-
dation for NAFLD patients may have substantial benefi-
cial impacts on society as well. It will first enhance the 
quality of life, health and well- being of NAFLD patients by 
reducing the burden of NAFLD progression to advanced 
liver diseases and more likely to be practical and thriving 
in the long term as it is the first non- calorie restriction 
approach. Second, it will contribute towards evidence- 
based policy making in GI food labelling and therapeutic 
dietary recommendations and will contribute to increase 
public awareness of dietary issues. The potential medical 
costs for a patient with NAFLD per year is between €354 
and €1163 in Europe.3 Thus, preventing NAFLD progres-
sion will reduce the burden on healthcare systems and 
clinical services as NAFLD patients have high- risk liver- 
related morbidities and metabolic comorbidities. Also, 
it may urge the food industries and services to adopt 
labelling GI values in nutrition facts labels of food prod-
ucts and to reformulate high GI foods to make them 
lower. However, this study protocol is subject to certain 
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limitations. First, the 2- week time frame of the interven-
tion, especially in light of isoenergetic diet, may not be 
long enough to observe significant changes in liver fat 
and microbiome. Second, findings from small sample size 
may not be generalisable to all patients with NAFLD so 
will require replication in larger long- term RCT.
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